Noteworthy advances in diabetes and obesity therapies include Amgen’s adjustment of dosing schedules for its obesity drug MariTide following Phase 2 data showing significant weight loss but high gastrointestinal side effects. Additionally, novel oral molecules demonstrating metabolic benefits comparable to GLP-1 receptor agonists without injection requirements entered early clinical testing. Vertex Pharmaceuticals reported encouraging cell therapy results for type 1 diabetes, with most patients achieving insulin independence in Phase 1/2 trials. Novo Nordisk disclosed ongoing amycretin studies showing potential for weight loss beyond current plateau levels.